



Southeast Louisiana VA Healthcare System Reorders CADScor Patches

Acarix, a leader in advanced acoustic-based cardiac diagnostics, today announces an advancement in the utilization of its CADScor® System within the Veterans Administration (VA) Healthcare network, the largest healthcare provider in the US. The Southeast Louisiana VA Healthcare System has reordered CADScor Patches in their Slidell and Baton Rouge locations to be used with the CADScor System for risk-stratification of symptomatic patients suspected of coronary artery disease (CAD) throughout various facilities within their system.

The Southeast Louisiana VA Healthcare System was the first VA location to place orders for CADScor System and patches in February, with approval of the CADScor System into their Standard Operating Procedure (SOP) in August. Since integrating the CADScor System into their SOP, the Southeast Louisiana VA Team has also aligned their Computerized Patient Record System (CPRS) with the SOP to ensure all relevant symptomatic patients suspected of CAD undergo a CADScor System Test.

In the past few months, the Acarix team has collaborated closely with the Southeast Louisiana VA Leadership Team, providing support to more than 100 Healthcare Professionals (HCPs) through various activities, including CADScor System in-servicing within their Cardiology group. Furthermore, the team has been actively engaged in monthly Primary Care meetings with the Chief of Cardiology, effectively developing awareness about the CADScor System.

"With the SOP approval and alignment of the CPRS, along with comprehensive training for HCPs, we anticipate an increase in CADScor System utilization throughout the VA Louisiana system. The initial reorders from Slidell and Baton Rouge are just the beginning of a trend we expect to continue into 2024," commented Fred Colen, Acting CEO of Acarix. "By providing a quick and easy non-invasive first-line diagnostic aid for assessing CAD risk, the CADScor System effectively streamlines the diagnostic process, enabling physicians to allocate resources more efficiently and elevate the overall standard of care for our nation's veterans in Louisiana. Our efforts, in collaboration with VA leadership there, have laid the groundwork for potential widespread adoption of the CADScor System despite the challenges associated with changing clinical practices."

For more information contact:

Fred Colen, acting CEO, email fred.colen@acarix.com

Christian Lindholm, CFO, phone +46 705 118333, email christian.lindholm@acarix.com



About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Erik Penser Bank AB (+46 8 463 83 00, certifiedadviser@penser.se) is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments

[Southeast Louisiana VA Healthcare System Reorders CADScor Patches](#)